For example, chemotherapy combined with trastuzumab has significantly reduced the mortality rate of Her2‐positive breast cancer, and has become the first‐line treatment strategy for Her2‐positive breast cancer patients.82 This evidence concerns the gene ERBB2 and breast cancer.